Untranslated

More Language

86-21-64556180

cpd-service@caerulumpharma.com

Ekhaya
Ngathi
Iimveliso
Izisombululo
Izibonelelo
- Downloadable
- Igalari yomfanekiso
Ii-FAQs
Qhagamshelana nathi

Ekhaya
Iimveliso
Iimolekyuli zeBioactive
Abanye
Intsholongwane yoMkhuhlane

Iintlobo zeemveliso

I-Antineoplastic
- I-ACC
- Adenosine A2A
- I-ALK
- I-Androgen receptor inhibitor
- I-Apoptosis evuselelayo
- ATR
- AXL
- I-BCl2-BH4
- Bcr-Abl
- I-BRAF
- I-BTK
- CDK
- Khk1
- I-CYP17
- DNA alkylating agent
- EED
- EGFR
- EP4
- ER
- FAK
- FGFR
- FLT3
- Glutaminase
- NDIYAVUMA
- I-IRA
- IKIT
- LXR
- MDM2
- MEK
- YAMET
- Nrf2
- P90RSK
- P97
- I-PAKS
- I-PARP
- PI3K
- Plk-1
- SMYD2
- SRC
- TOPK
- VEGFR
Iziyobisi ze-Hypoglycemic
Abanye
- 5HT
- AMPK
- Arginase
- CRF-1
- CXCR2
- FLAP
- FXR
- GABA
- Gi activator
- GR
- JAK
- LABA
- iimachRs
- NF-kB
- I-NRTI
- PPAR
- RIP1
- I-S1PR
- SGC
- SYK
- α2δ-1
- αIIbβ3
- β2-adrenoceptor
- σ1

Intsholongwane yoMkhuhlane

CAT #	Igama lemveliso	Inkcazo
CPD2051	Baloxavir	I-Baloxavir yi-arhente echasene nomkhuhlane ekhutshwe kwi-patent WO 2017104691 A1.

Qhagamshelana nathi

No. 401, 4th Floor, Building 6, Quwu Road 589, Minhang District, 200241 Shanghai, China
86-21-64556180
ETshayina:
sales-cpd@caerulumpharma.com
Amazwe ngamazwe:
cpd-service@caerulumpharma.com

Ukubuza

Ngemibuzo malunga neemveliso zethu, nceda ushiye i-imeyile yakho kunye nathi kwaye siya kuqhagamshelana phakathi kweeyure ezingama-24.Ukubuza

Iindaba zamva

I-AstraZeneca ifumana unyuso lolawulo lwamachiza e-oncology

I-AstraZeneca ifumana unyuso lolawulo lwe...

I-AstraZeneca ifumene ukongezwa okuphindwe kabini kwipotfoliyo yayo ye-oncology ngoLwesibini, emva kokuba abalawuli base-US naseYurophu bamkele ukungeniswa kolawulo lwamachiza ayo, inyathelo lokuqala lokuphumelela ukuvunywa kwala mayeza. ...

Iindlela eziPhezulu ze-7 kuPhando lwezoPhando kwi-2018

IiNdlela ezi-7 eziphambili kuPhando lwaMayeza...

Ukuba phantsi koxinzelelo oluhlala lukhula lokukhuphisana kwimeko yezoqoqosho kunye nethekhinoloji ecela umngeni, iinkampani zamayeza kunye nebhayoloji kufuneka ziqhubeke zenza izinto ezintsha kwiinkqubo zazo zeR&D ukuze zihlale phambili ...

I-ARS-1620: I-inhibitor entsha ethembisayo ye-KRAS-mutant cancers

I-ARS-1620: Isithinteli esitsha esithembisayo se-K...

Ngokophononongo olupapashwe kwiSeli, abaphandi baye baphuhlisa inhibitor ethile ye-KRASG12C ebizwa ngokuba yi-ARS-1602 ebangele ukuhlehla kwethumba kwiimpuku. "Olu phononongo lubonelela ngobungqina bokuba i-KRAS eguqukayo inokuba...

I-AstraZeneca ifumana unyuso lolawulo lwamachiza e-oncology

I-AstraZeneca ifumana unyuso lolawulo lwe...

I-AstraZeneca ifumene ukongezwa okuphindwe kabini kwipotfoliyo yayo ye-oncology ngoLwesibini, emva kokuba abalawuli base-US naseYurophu bamkele ukungeniswa kolawulo lwamachiza ayo, inyathelo lokuqala lokuphumelela ukuvunywa kwala mayeza. ...

Iindlela eziPhezulu ze-7 kuPhando lwezoPhando kwi-2018

IiNdlela ezi-7 eziphambili kuPhando lwaMayeza...

Ukuba phantsi koxinzelelo oluhlala lukhula lokukhuphisana kwimeko yezoqoqosho kunye nethekhinoloji ecela umngeni, iinkampani zamayeza kunye nebhayoloji kufuneka ziqhubeke zenza izinto ezintsha kwiinkqubo zazo zeR&D ukuze zihlale phambili ...

prev

next

© Copyright - 2015-2022 : Onke Amalungelo Agciniwe.

Ii-FAQs
Downloadable
Qhagamshelana nathi

Thumela i-imeyile

Ikhowudi yeQR

Incoko ka-WhatsApp kwi-Intanethi!

TOP

Previous Maximize